Mesothelioma

Researchers Found a Relationship Between GISTs and Peritoneal Mesothelioma

Scientists may have found an easy way to identify peritoneal mesothelioma, making it easier to detect and catch the cancer earlier. These researchers may have found a link between peritoneal mesothelioma and gastrointestinal stromal tumors. The research done in the division of surgical oncology at University of California San Diego[…]

Read More »

Researchers Possibly Found a MicroRNA Biomarker to Diagnose Mesothelioma

Italian researchers have potentially found a new biomarker for mesothelioma. The biomarker is a microRNA signature. This would allow doctors to determine if someone’s cancer is mesothelioma or another type of cancer quickly. Mesothelioma is a notoriously hard to treat cancer and early diagnosis is one of the keys to[…]

Read More »

Report Shows that Asbestos Ban Would Benefit Countries Around the World

Banning asbestos could soon be a reality after a study linked asbestos, a toxic naturally occurring mineral, to mesothelioma, lung cancer, and other cancers. The report linked asbestos with different asbestos related diseases in 70 countries. The report was published in May by Environmental Health Perspectives, which is supported by[…]

Read More »

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Primary Outcome Measures Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ] Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug[…]

Read More »

An Inhalable Gene Therapy is Being Tested for Mesothelioma

An inhalable gene therapy could potentially be approved for use in mesothelioma patients. Researchers in Japan have created two different tumor suppressing drugs that work by targeting genetic mutations. The drugs were created for non-small cell cancer and pleural mesothelioma. They are both doing well in the laboratory. The drugs[…]

Read More »

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Primary Outcome Measures Progression-free survival [ Time Frame: From date of randomisation until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 18 months ] Progression-free survival is the determined by modified RECIST (pleural disease), RECIST 1.1 (for non-pleural disease), investigator reported progression[…]

Read More »

Drug Repurposing for Mesothelioma

Research at Temple University is looking at four different drug compounds, all used for noncancerous conditions, for treating mesothelioma. The research is part of a drug repurposing project, which tests drugs not typically used for illnesses like cancer to see if they work on the disease. Drug repurposing has become[…]

Read More »

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Primary Outcome Measures Modification(s) in the immune blood markers of treated subjects on treatment. [ Time Frame: Assessment: between week 4 and 6 after the first dose of the treatment ] Modification(s) in the immune blood markers including cytokines, immune cells and serum autoantibody level of treated subjects. Modification(s) in the immune blood markers[…]

Read More »

SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma

Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]

Read More »